FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:422-424 July 23, 2009 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cooper, L. T. PubMed Citation

To the Editor: Supportive care is the mainstay of therapy for acute myocarditis. In his review article on this topic, Cooper (April 9 issue)¹ notes that studies of immunosuppressive therapy have not shown a clear beneficial role, as compared with usual care. Thus, the beneficial effect of immunosuppressive therapy remains controversial. Treatment that is based on the presence of human leukocyte antigen may be associated with improved outcomes.¹ However, are there other ways to predict who is likely to benefit from immunosuppressive therapy? In one trial, prednisolone that was administered to patients who did not have a response to other . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.